ArticleThe Lancet. Oncology2019

Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.

Panagiotis A Konstantinopoulos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.